{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:26:52Z","timestamp":1780583212407,"version":"3.54.1"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.09.002","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"395-407","source":"Crossref","is-referenced-by-count":16,"title":["Advances in the biology and therapy of patients with chronic myeloid leukaemia"],"prefix":"10.1016","volume":"22","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.09.002_bib1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2741\/1791","article-title":"Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?","volume":"11","author":"Mughal","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.beha.2009.09.002_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3810\/pgm.1999.09.686","article-title":"Chronic myelogenous leukemia. Curable with early diagnosis and treatment","volume":"106","author":"Hill","year":"1999","journal-title":"Postgrad Med"},{"key":"10.1016\/j.beha.2009.09.002_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2009.09.002_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s004320050228","article-title":"Chronic myelogenous leukemia: molecular and cellular aspects","volume":"124","author":"Pasternak","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.09.002_bib6","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib7","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1073\/pnas.93.23.13137","article-title":"Blastic transformation of p53-deficient bone marrow cells by p2lObcr\/abl tyrosine kinase","volume":"93","author":"Skorski","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beha.2009.09.002_bib8","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1016\/S0092-8674(00)81079-X","article-title":"Role of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.09.002_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","article-title":"Alterations ofP53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia","volume":"38","author":"Beck","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.09.002_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","article-title":"The RB and p53 pathways in cancer","volume":"2","author":"Sherr","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2009.09.002_bib11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2009.09.002_bib12","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.09.002_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.18553\/jmcp.2007.13.s8-a.4","article-title":"Chronic myeloid leukemia in 2007","volume":"13","author":"Sessions","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.beha.2009.09.002_bib14","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.09.002_bib15","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.09.002_bib16","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.09.002_bib17","article-title":"NCCN: clinical practice guidelines in oncology","author":"National Comprehensive Cancer Network","year":"2009","journal-title":"Chronic Myelogenous Leuk"},{"key":"10.1016\/j.beha.2009.09.002_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib20","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib21","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.09.002_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.beha.2009.09.002_bib23","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1200\/jco.2007.25.18_suppl.7045","article-title":"Discontinuation and dose modification of imatinib in clinical practice","volume":"25","author":"Hamdan","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib24","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.09.002_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors \u2013 review and recommendations for \u2018harmonizing\u2019 current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib26","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3816\/CLM.2007.s.002","article-title":"Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges","volume":"7","author":"Jabbour","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.beha.2009.09.002_bib27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.09.002_bib28","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib29","unstructured":"Sprycel (dasatinib) [package insert]. 2007."},{"key":"10.1016\/j.beha.2009.09.002_bib30","unstructured":"Dasatinib prescribing information, May 2008."},{"key":"10.1016\/j.beha.2009.09.002_bib31","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib32","first-page":"372","article-title":"Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: A two-year update of the START-C study","volume":"93","author":"Cervantes","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.09.002_bib33","first-page":"48","article-title":"Dasatinib compared with high-dose imatinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) after failure of standard-dose imatinib \u2013 A two-year update of the START-R study","volume":"93","author":"Rousselot","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.09.002_bib34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/jco.2007.25.18_suppl.7004","article-title":"Dasatinib 50mg or 70mg BID compared to 100mg or 140mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: One-year results of CA180034","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib35","unstructured":"Tasigna (nilotinib) [package insert]. 2007."},{"key":"10.1016\/j.beha.2009.09.002_bib36","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.V112.11.3238.3238","article-title":"Nilotinib in Chronic Myeloid Leukemia Patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V112.11.3215.3215","article-title":"Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP)","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood.V112.11.130.130","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V112.11.185.185","article-title":"Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): Results of an European LeukemiaNet prospective study comparing 400 mg and 800 mg front-line","volume":"112","author":"Baccarani","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib40","first-page":"170","article-title":"Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood.V112.11.181.181","article-title":"High and early rates of cytogenetic and molecular response with nilotinib 800mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: Results of a phase 2 trial of the GIMEMA CML Working Party","volume":"112","author":"Rosti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib42","first-page":"74","article-title":"Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib43","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.beha.2009.09.002_bib44","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.V112.11.1098.1098","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib45","doi-asserted-by":"crossref","first-page":"368s","DOI":"10.1200\/jco.2007.25.18_suppl.7046","article-title":"phase I study of INNO-406, a dual inhibitor of Abl and Lyn kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory, or intolerant of imatinib","volume":"25","author":"Craig","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib46","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF- 1R\/aurora kinase inhibitor XL228 in patients with Ph++Leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib47","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.beha.2009.09.002_bib48","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1124\/mol.106.033308","article-title":"The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr\/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation","volume":"72","author":"Rahmani","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.beha.2009.09.002_bib49","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib50","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1358\/dof.2007.032.04.1094476","article-title":"Panobinostat. Histone deacetylase (HDAC) inhibitor, apoptosis inducer, oncolytic","volume":"32","author":"Revill","year":"2007","journal-title":"Drugs Future"},{"key":"10.1016\/j.beha.2009.09.002_bib52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood.V110.11.907.907","article-title":"Phase IA\/II study of oral LBH589, a novel deacetylase inhibitor (DACi), administered on 2 schedules, in patients with advanced hematologic malignancies","volume":"110","author":"Spencer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib53","doi-asserted-by":"crossref","first-page":"1041a","DOI":"10.1182\/blood.V110.11.1041.1041","article-title":"Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia (CML) cells sensitive and resistant to imatinib mesylate","volume":"110","author":"Dai","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib54","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib55","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-07-0835","article-title":"Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation","volume":"13","author":"Dasmahapatra","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"18S","key":"10.1016\/j.beha.2009.09.002_bib56","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1200\/jco.2007.25.18_suppl.7066","article-title":"A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia","volume":"25","author":"Kadia","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib57","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.10436","article-title":"Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia","volume":"94","author":"O'Brien","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.09.002_bib58","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.11620","article-title":"Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase","volume":"98","author":"O'Brien","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.09.002_bib59","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1200\/jco.2008.26.15_suppl.7021","article-title":"Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation","volume":"26","author":"Cortes","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib60","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.09.002_bib61","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5\u2032-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2009.09.002_bib62","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"Issa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib63","first-page":"183","article-title":"Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)","volume":"112","author":"Guilhot","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2009.09.002_bib64","first-page":"193","article-title":"Randomized clinical trial for the optimization of imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV","volume":"94","author":"Hehlmann","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.beha.2009.09.002_bib65","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2009.09.002_bib66","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib67","first-page":"448","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: high survival rate following allogeneic HSCT after imatinib failure: results of the german CML study IV","volume":"112","author":"Saussele","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2009.09.002_bib68","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib69","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.449.449","article-title":"Dasatinib efficacy in patients with chronic myelogenous leukemia in chronic phase (CML-CP) and pre-existing BCR-ABL mutations","volume":"112","author":"Muller","year":"2008","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2009.09.002_bib71","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.09.002_bib72","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.09.002_bib73","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.beha.2009.09.002_bib74","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T06:06:03Z","timestamp":1634277963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000668"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.09.002","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}